Oric Pharmaceuticals (NASDAQ:ORIC) CEO Jacob Chacko Sells 37,461 Shares of Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 37,461 shares of the firm’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $12.32, for a total value of $461,519.52. Following the transaction, the chief executive officer directly owned 531,419 shares in the company, valued at approximately $6,547,082.08. This represents a 6.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Jacob Chacko also recently made the following trade(s):

• On Wednesday, October 1st, Jacob Chacko sold 53,001 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.05, for a total value of $638,662.05.
• On Tuesday, September 30th, Jacob Chacko sold 34,538 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.01, for a total value of $414,801.38.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.80, for a total value of $1,350,000.00.

Oric Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ ORIC opened at $14.28 on Thursday. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -7.56 and a beta of 1.68. Oric Pharmaceuticals, Inc. has a 1-year low of $3.90 and a 1-year high of $14.93. The stock’s 50-day moving average is $10.59 and its 200 day moving average is $8.66.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). On average, analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Analyst Ratings Changes

ORIC has been the topic of several recent research reports. Zacks Research upgraded Oric Pharmaceuticals to a “hold” rating in a research report on Tuesday, August 12th. HC Wainwright reduced their price target on Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Wedbush restated an “outperform” rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. Guggenheim initiated coverage on Oric Pharmaceuticals in a research report on Thursday, September 4th. They set a “buy” rating and a $18.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, August 14th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.29.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in shares of Oric Pharmaceuticals in the 2nd quarter worth approximately $1,084,000. Tower Research Capital LLC TRC grew its position in shares of Oric Pharmaceuticals by 1,293.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company’s stock worth $119,000 after buying an additional 10,913 shares during the last quarter. Eventide Asset Management LLC bought a new stake in shares of Oric Pharmaceuticals in the 2nd quarter worth approximately $9,657,000. BNP Paribas Financial Markets grew its position in shares of Oric Pharmaceuticals by 1,102.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 86,755 shares of the company’s stock worth $881,000 after buying an additional 79,540 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Oric Pharmaceuticals in the 2nd quarter worth approximately $352,000. 95.05% of the stock is currently owned by institutional investors.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.